Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib, page-17

Many did go in hard early, me included Mate. I have now reached in the back pockets to double I mean tripled down at 17c and these lows. I have been excited since the first IPO presentation when there was only the Chlortoxin Car-T, now we have a very solid pipeline and way further down the track. I look forward to looking back on this post in a year or two when we have more data, partnerships and hopefully a few fast track designations.